Treats hypertension. ANDA 76070, held by Valeant Pharms North. Nifedipine.
As of Nov 16, 2026, ANDA 76070 (Nifedipine), held by Valeant Pharms North, was first approved by FDA on Aug 16, 2002, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Nifedipine extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 16, 2002 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nifedipine90MG · tablet, extended release;oral | Nifedipine | Rx |
| Nov 26, 2012 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 16, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters